Last reviewed · How we verify
subretinal injection of rAAV.hPDE6A
At a glance
| Generic name | subretinal injection of rAAV.hPDE6A |
|---|---|
| Also known as | Gene therapy |
| Sponsor | STZ eyetrial |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PDE6A Gene Therapy for Retinitis Pigmentosa (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- subretinal injection of rAAV.hPDE6A CI brief — competitive landscape report
- subretinal injection of rAAV.hPDE6A updates RSS · CI watch RSS
- STZ eyetrial portfolio CI